Tuesday's Stocks to Watch: UNH, Moderna, DG, and More
Over the past weekend, the new CEO of UnitedHealth (UNH) bought shares after the sell-off. UNH stock gained 8.21% to close at $315.89. This is the stock to watch, as value investors bet the forward P/E of 12.45 times is too low to ignore.Other notable insider sales include Apple (AAPL). Its principal accounting officer, Chris Kondo, sold 4,486 shares. He now holds 15,553 shares. Uber Technologies (UBER) saw Jill Hazelbaker, a chief marketing officer, sell 34,884 shares for $86 a share. The CMO now holds 112,589 shares. Disney’s (DIS) executive vice president, Brent Woodford, sold 1,000 shares for $110.80. Woodford has 47,220 shares left in Disney.On Monday, Novavax (NVAX) gained 15.01% to squeeze short sellers, who have a 26.14% short interest. The FDA approved its COVID-19 vaccine for adults 65 years and older, lifting Moderna (MRNA) shares. Watch out for MRNA stock pulling back, since the Novavax vaccine approval risks hurting demand for Moderna’s product.Dollar General (DG) is about to break out above $100, a price not seen since September 2023. The discount retailer focused on its core business model. It improved its operational processes and has a good chance of reducing shrink (theft). Expect this firm to post strong earnings. It might raise its guidance for the quarter ahead.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


